NVP-AUY922 is primarily utilized in cancer research due to its role as a potent inhibitor of heat shock protein 90 (HSP90). This protein plays a critical role in the stabilization and function of various oncogenic client proteins, making it a key target in oncology. By inhibiting HSP90, NVP-AUY922 disrupts the chaperone function, leading to the degradation of these client proteins, which are essential for cancer cell survival and proliferation. This mechanism makes it a promising candidate for the treatment of various cancers, including breast, lung, and prostate cancer. Additionally, it is being studied in combination therapies to enhance the efficacy of other anticancer agents. Its application extends to preclinical models, where it helps in understanding the molecular pathways involved in tumor growth and resistance to treatment.